OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.

OrbiMed Private Investments VIIIĀ invests primarily in venture capital stage opportunities in North America and Europe, with a focus on biotechnology, medical device, and diagnostics companies. This fund targets investments from $10 million to $100 million across approximately 40 portfolio companies.

OrbiMed Asia Partners IV invests primarily in China and India, from venture capital through growth stage across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. This fund targets investments from $10 million to $100 million in approximately 20 portfolio companies.

OrbiMed Royalty & Credit Opportunities III invests globally through providing structured credit and royalty monetization financing solutions for healthcare companies and institutions. This fund generally invests from $10 million to $150 million per opportunity.

Read More

Source: Business Wire